Last reviewed · How we verify
Claritin (loratadine)
Loratadine (Claritin) is a second-generation, non-sedating antihistamine first approved in 1993. Now OTC and available generically worldwide, it provides 24-hour allergy relief with once-daily dosing and minimal drowsiness.
At a glance
| Generic name | loratadine |
|---|---|
| Also known as | Claritin, Alavert, Clarityn |
| Sponsor | Generic (originally Schering-Plough) |
| Drug class | Second-generation antihistamine |
| Target | Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1 |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1993-04-12 (United States) |
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Chronic idiopathic urticaria
- Common cold
- Nasal congestion
- Nasal discharge
- Seasonal allergic rhinitis
- Sneezing
- Vasomotor rhinitis
Common side effects
Key clinical trials
- A Double-Blind, Parallel, Randomized, Placebo Controlled Trial to Evaluate Onset of Action of Loratadine and Fexofenadine in Subjects With Seasonal Allergic Rhinitis in a Pollen Challenge Chamber (Phase 4)
- A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age (Phase 3)
- Effect Comparison of Acupuncture Combined With Moxibustion and Loratadine for Perennial Allergic Rhinitis: a Randomized Controlled Trial (Phase 2)
- Comparative, Randomized, Single-Dose, 3-way Crossover Bioavailability Study of Sandoz Inc. and Schering (Claritin) 10 mg Loratadine Tablets In Healthy Adult Male Volunteers Under Fed and Fasting Condi (Phase 1)
- A Comparative Study of Diosmin-Hesperidin and Loratadine for the Prevention of G-CSF Induced Bone Pain in Patients With Hematological Malignancies (NA)
- A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of BMS-986446, an Anti-MTBR Tau (Phase 1)
- Effect of Iron Repletion in Women With Chronic Cough and Iron Deficiency (NA)
- Assessing the Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang as Adjuvant Treatment in Mild COVID-19 Patients on Home Recovery Program in Singapore: a Randomised, Double-blind, Placebo-controlled (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Claritin CI brief — competitive landscape report
- Claritin updates RSS · CI watch RSS
- Generic (originally Schering-Plough) portfolio CI